Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium.
Saved in:
| Title: | Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. |
|---|---|
| Authors: | Byonanebye DM; Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.; School of Public Health, Makerere University, Kampala, Uganda., Polizzotto MN; Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia., Neesgaard B; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Sarcletti M; Department of Dermatology, Venerology and Allergology, Medical University Innsbruck, Innsbruck, Austria., Matulionyte R; Department of Infectious Diseases and Dermatovenerology, Faculty of Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania., Braun DL; Division of Infectious Diseases and Hospital Epidemiology, Switzerland Swiss HIV Cohort Study (SHCS), Institute of Medical Virology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Castagna A; San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milano, Italy., de Wit S; CHU Saint Pierre, Infectious Diseases, Université Libre de Bruxelles, Brussels, Belgium., Wit F; AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort, HIV Monitoring Foundation, Amsterdam, The Netherlands., Fontas E; Nice HIV Cohort, Université Côte d'Azur et Centre Hospitalier Universitaire, Nice, France., Vehreschild JJ; Medical Department 2, Hematology/Oncology, University Hospital of Frankfurt, Frankfurt, Germany.; Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany., Vesterbacka J; Swedish InfCare HIV Cohort, Karolinska University Hospital, Huddinge, Sweden., Greenberg L; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK., Hatleberg C; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Garges H; ViiV Healthcare, RTP, North Carolina, USA., Gallant J; Gilead Sciences, Foster City, California, USA., Volny Anne A; EATG European AIDS Treatment Group, Brussels, Belgium., Öllinger A; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Mozer-Lisewska I; Poznan University of Medical Sciences, Poznan, Poland., Surial B; Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Spagnuolo V; San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Milano, Italy., Necsoi C; CHU Saint Pierre, Infectious Diseases, Université Libre de Bruxelles, Brussels, Belgium., van der Valk M; AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort, HIV Monitoring Foundation, Amsterdam, The Netherlands.; Division of Infectious Diseases, Department of Internal Medicine, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands., Mocroft A; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK., Law M; Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia., Ryom L; CHIP, Centre of Excellence for Health, Immunity, and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark., Petoumenos K; Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia. |
| Corporate Authors: | RESPOND study group |
| Source: | HIV medicine [HIV Med] 2022 Sep; Vol. 23 (8), pp. 895-910. Date of Electronic Publication: 2022 Mar 01. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 100897392 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1293 (Electronic) Linking ISSN: 14642662 NLM ISO Abbreviation: HIV Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
